obesity drugs
-
Obesity Drugs Are Becoming A Format And Margin Trade
Lilly’s Europe launch plan for an oral obesity pill, Novo Nordisk’s next-wave data, Chugai’s licensed discovery, and Hanmi’s muscle-preserving pipeline all suggest the GLP-1 trade is moving beyond a simple two-stock growth narrative.